{
  "abstract": "Pasireotide, a somatostatin analog with high affinity for somatostatin receptor 5 (SSTR5), is frequently used to treat residual or recurrent pituitary adenomas, but it often induces hyperglycemia by suppressing glucagon-like peptide-1 (GLP-1) secretion. Although GLP-1 receptor agonists (GLP-1RAs) have been reported to be effective for pasireotide-induced hyperglycemia, no established treatment strategy currently exists. The present report describes the first documented use of once-weekly subcutaneous tirzepatide in a patient with pasireotide-induced hyperglycemia that remained inadequately controlled despite oral GLP-1RA therapy. A 48-year-old woman without a history of glucose intolerance was diagnosed with a GH/TSH-producing pituitary adenoma/PitNET. Transsphenoidal surgery was performed, followed by initiation of pasireotide for the residual tumor. Subsequently, the patient developed progressive hyperglycemia, with the hemoglobin A1c (HbA1c) level increasing from 6.5% to 7.7%. Oral sitagliptin and semaglutide were sequentially introduced; however, glycemic control remained suboptimal. Upon switching to once-weekly subcutaneous tirzepatide, the HbA1c level decreased markedly from 7.7% to 6.3%, along with an improvement in random blood glucose levels. In conclusion, once-weekly subcutaneous tirzepatide may be a therapeutic option for selected patients with pasireotide-induced hyperglycemia. However, further studies are needed to determine whether its effects differ from those of intensified GLP-1RA therapy.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": null,
  "author_total": 6,
  "authors": [
    {
      "name": "Yuichiro Iwamoto"
    },
    {
      "name": "Kaoru Yamashita"
    },
    {
      "name": "Yasufumi Seki"
    },
    {
      "name": "Kosaku Amano"
    },
    {
      "name": "Atsuhiro Ichihara"
    },
    {
      "name": "Hideaki Kaneto"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/7cd3wwh9sf3k6.bib",
  "cited_by": 1,
  "doi": "10.1507/endocrj.ej26-0396",
  "fulltext_url": "https://www.jstage.jst.go.jp/article/endocrj/advpub/0/advpub_EJ26-0396/_article",
  "id": "7cd3wwh9sf3k6",
  "issns": [
    "1348-4540",
    "0918-8959"
  ],
  "landing_url": "https://www.jstage.jst.go.jp/article/endocrj/advpub/0/advpub_EJ26-0396/_article",
  "language": null,
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "jstage-journal",
      "medicine/endocrinology-metabolism"
    ],
    [
      "openalex",
      "2712|Pituitary Gland Disorders and Treatments"
    ]
  ],
  "openalex": "W7212270137",
  "pdf_url": "https://www.jstage.jst.go.jp/article/endocrj/advpub/0/advpub_EJ26-0396/_pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-09-12",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/7cd3wwh9sf3k6.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:20Z",
      "native_id": "10.1507/endocrj.ej26-0396",
      "source": "jstage",
      "url": "https://www.jstage.jst.go.jp/article/endocrj/advpub/0/advpub_EJ26-0396/_article"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2712|Pituitary Gland Disorders and Treatments",
      "subfield": "endocrinology-metabolism"
    }
  ],
  "title": "Tirzepatide for pasireotide-induced hyperglycemia in a GH/TSH-producing pituitary adenoma/PitNET: a case report and literature review",
  "title_text": "Tirzepatide for pasireotide-induced hyperglycemia in a GH/TSH-producing pituitary adenoma/PitNET: a case report and literature review",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:17:20Z",
  "url": "https://research.draconitic.com/paper/7cd3wwh9sf3k6",
  "venue": "Endocrine Journal",
  "versions": []
}